Obalon Therapeutics

50 articles about Obalon Therapeutics

• ReShape Lifesciences Closes First Day of Trading on the NASDAQ Capital Market

  6/17/2021

  ReShape Lifesciences Inc., a global weight-loss solutions leader, announced that its common stock effectively traded at a first day volume of over 3.5 million shares on The Nasdaq Capital Market under the ticker symbol "RSLS", following the previously announced completion of its merger with Obalon Therapeutics, Inc.

• ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Announce Anticipated Closing of Merger

  6/15/2021

  ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. announced the anticipated closing of their previously announced merger to be effective after the close of the market, June 15, 2021.

• Reminder: Obalon Therapeutics Continues to Urge Stockholders to Vote FOR All Proposals Related to Merger with ReShape Lifesciences

  5/24/2021

  Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, is taking this opportunity to remind its stockholders to vote on all the proposals related to the proposed merger with ReShape Lifesciences Inc. in advance of the upcoming reconvened special meeting of Obalon stockholders n

• Obalon Therapeutics Continues to Urge Stockholders to Vote FOR All Proposals Related to Merger with ReShape Lifesciences

  5/21/2021

  Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, is taking this opportunity to remind its stockholders to vote on all the proposals related to the proposed merger with ReShape Lifesciences Inc. in advance of the upcoming reconvened special meeting of Obalon stockholders

• Obalon Therapeutics Stockholders Special Meeting Adjourned to May 25, 2021

  5/18/2021

  Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, announced that the special shareholders meeting for Obalon Stockholders

• Obalon Announces First Quarter 2021 Financial Results

  5/12/2021

  Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2021.

• Obalon Announces Fourth Quarter and Full Year 2020 Financial Results

  3/13/2021

  Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2020.

• Obalon Announces Third Quarter 2020 Financial Results

  11/6/2020

  Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2020. Financial results for the third quarter of 2020 Revenue for the third quarter of 2020 was $44,000, compared to $0.3 million for the third quarter of 20

• Obalon Announces Consulting Agreement As Part of Strategy To Seek Coverage and Reimbursement for The Obalon Balloon System

  8/13/2020

  Obalon Therapeutics, Inc. announced that it has executed a consulting agreement with Blue Ox Healthcare Partners, LLC, a private equity firm focused on commercial-ready companies bringing technology enabled innovation to healthcare, especially those involved in precision health, healthcare delivery, and affordability.

• Obalon Announces Second Quarter 2020 Financial Results

  7/30/2020

  Obalon Therapeutics, Inc., a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announced its financial results for the second quarter ended June 30, 2020.

• Obalon Announces First Quarter 2020 Financial Results and Business Update

  6/19/2020

  Obalon Therapeutics, Inc., a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announced its financial results for the first quarter ended March 31, 2020 and provided a business update.

• Obalon Announces Further Impacts Related To Covid-19 Crisis and Current Business Environment

  5/11/2020

  Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces changes related to the impacts of the Covid-19 crisis and current business environment on its business, organization and strategic options. As previously announced, the overall uncertai

• William Plovanic Resigns as President and Chief Executive Officer and Will Continue to Serve Solely as DirectorObalon’s Executive Chairman, Andy Rasdal, will reassume CEO position

  5/8/2020

  Obalon Therapeutics, Inc., a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that William Plovanic, the Company’s President and CEO has announced his resignation in order to accept another position.

• Obalon Gas-Filled Balloon Not Subject of Fourth FDA Letter to Health Care Providers Related To Serious Risks, Including Death, With Liquid-Filled Intragastric Balloons

  4/28/2020

  Obalon reported no device-related serious adverse events (0%) for first 141 patients completing therapy in post-approval study to FDA

• Obalon Engages Canaccord Genuity to Explore Financial and Strategic Alternatives

  3/25/2020

  Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that its Board of Directors has decided to explore potential financial and strategic alternatives intended to enhance stockholder value. The Company has engaged Canaccord Genuity LLC as its financial advisor. Th

• Obalon Temporarily Suspends New Patient Sales at Its Retail Treatment Centers Due to Coronavirus Pandemic

  3/17/2020

  No patients or employees have been found to be symptomatic or positive for the virus, yet patient, employee, and public health remain Obalon’s highest priority

• Obalon Announces Fourth Quarter and Full Year 2019 Financial Results

  2/27/2020

  Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2019.

• Obalon Announces Opening of Second Retail Treatment Center in Orange County, CACompany continues to execute on its strategy to develop retail treatment sites focused exclusively on treatment with the Obalon Balloon System™

  2/20/2020

  Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has opened its second Company-managed retail treatment center.

• Obalon Schedules Fourth Quarter and Year-End 2019 Financial Results Conference Call for February 27, 2020 at 8:30 a.m. Eastern Time

  2/13/2020

  SAN DIEGO, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it plans to release its fourth quarter and year-end 2019 financial results before the market opens on Thursday, February 27, 2020 and hold a conference call at 8:30 AM Eastern Time (5:30 AM Pacific Time) to discuss the Company's financial resu

• Obalon Enters into New Stock Purchase Agreement with Lincoln Park Capital Fund

  2/7/2020

  Obalon Therapeutics, Inc. announces that it has entered into a new common stock purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor, for up to $15 million.